PHAR investigators, in partnership with Sunovion Pharmaceuticals, developed clinical consensus on the use of on-demand treatments for Parkinson’s disease (PD) by convening experts to participate in a RAND/UCLA modified Delphi panel. In most evaluated scenarios, panelists agreed on-demand treatment is appropriate for PD patients with OFF episodes, especially for patients experiencing a significant functional impact. A summary of the process and consensus statements were presented as a poster at the 4th Pan American Parkinson’s Disease and Movement Disorders Congress today and can be viewed here. The accompanying abstract was also published in the May supplement issue of Movement Disorders Clinical Practice.